Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real‐world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions
Vincenzo De Falco, Gabriella Suarato, Rossella Napolitano, et al.
International Journal of Cancer (2023) Vol. 153, Iss. 1, pp. 133-140
Open Access | Times Cited: 9

Showing 9 citing articles:

Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study
Hildur Helgadóttir, Lars Ny, Gustav Ullenhag, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 115, Iss. 9, pp. 1077-1084
Open Access | Times Cited: 14
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Xue Bai, Shaheen Ahmed, Charlotte Grieco, et al.
EClinicalMedicine (2023) Vol. 65, pp. 102290-102290
Open Access | Times Cited: 14
Real‐Life Cohort of Patients With Resected High‐Risk Melanoma Treated by Adjuvant Anti‐PD1 Therapy
Liza Benzoni, Anaïs Eberhardt, S. Milley, et al.
Cancer Medicine (2025) Vol. 14, Iss. 6
Open Access
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis
Manja Bloem, Melissa M. de Meza, Alfons J.M. van den Eertwegh, et al.
British Journal of Cancer (2025)
Closed Access
Real-Life Outcomes of Adjuvant Targeted Therapy and Anti-PD1 Agents in Stage III/IV Resected Melanoma
Gabriele Roccuzzo, Paolo Fava, Chiara Astrua, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 3095-3095
Open Access | Times Cited: 3
Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US
Eric D. Whitman, Todor Totev, Shan Jiang, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies
Danai Dima, Nerea Lopetegui‐Lia, Olisaemeka Ogbue, et al.
Cancer Medicine (2024) Vol. 13, Iss. 12
Open Access
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma – Results of systematic literature research
Teresa Amaral, Lena Nanz, Lina María Serna-­Higuita, et al.
European Journal of Cancer (2024) Vol. 215, pp. 115160-115160
Open Access
Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program
Pietro Quaglino, Paolo A. Ascierto, Francesca Consoli, et al.
Cancer Management and Research (2023) Vol. Volume 15, pp. 1271-1281
Open Access
Page 1

Scroll to top